Drug interactions
Pralatrexate + Tisagenlecleucel
Severity: Major
Pralatrexate and Tisagenlecleucel: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Pralatrexate is an antifolate cytotoxic that causes myelosuppression and mucositis, and tisagenlecleucel recipients are already at risk of prolonged cytopenias and infection. Giving them together may impair CAR-T expansion and increase the risk of serious infection.
What this interaction means in plain words
Pralatrexate and Tisagenlecleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Pralatrexate belongs to Oncology; Tisagenlecleucel belongs to Oncology.
Why it happens
Additive cytotoxic and immunosuppressive effects; chemotherapy may also reduce CAR-T cell persistence and function.
What to do
Avoid pralatrexate around the time of CAR-T infusion unless clearly needed, and follow the CAR-T product labeling on washout. If used, monitor blood counts closely and give infection prophylaxis.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Pralatrexate and Tisagenlecleucel, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Pralatrexate
Other interactions of Tisagenlecleucel
Frequently asked questions
Can I take Pralatrexate with Tisagenlecleucel?
MediHelp rates the interaction as major. Pralatrexate and Tisagenlecleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Pralatrexate is an antifolate cytotoxic that causes myelosuppression and mucositis, and tisagenlecleucel recipients are already at risk of prolonged cytopenias and infection. Giving them together may impair CAR-T expansion and increase the risk of serious infection.
How serious is the interaction between Pralatrexate and Tisagenlecleucel?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid pralatrexate around the time of CAR-T infusion unless clearly needed, and follow the CAR-T product labeling on washout. If used, monitor blood counts closely and give infection prophylaxis.
What other medicines interact with Pralatrexate?
MediHelp also lists interactions of Pralatrexate with, for example, Adenovirus types 4 and 7 live, Axicabtagene ciloleucel, Brexucabtagene autoleucel. The full list is on the Pralatrexate page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
